(April 13, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it is now acting as the exclusive distributor of the NexStent™ carotid stent and Monorail™ delivery system in Europe and certain other international markets. The NexStent™ Monorail™ system, developed and manufactured by EndoTex Interventional Systems, Inc., recently received CE Mark for commercialization in Europe and certain other international markets. It has not yet been approved for commercialization in the United States.

"Our alliance with EndoTex demonstrates Boston Scientific's ability to provide the most innovative technology to our customers quickly," said Matthew Jenusaitis, President of Boston Scientific's Peripheral Interventions business. "The NexStent carotid stent, used in combination with the Boston Scientific FilterWire EZ™ embolic protection system, offers patients a less-invasive treatment alternative to the traditional surgical procedure known as a carotid endarterectomy."

"We have enjoyed a productive relationship with Boston Scientific as we collaborated on the CABERNET trial and now as we launch the NexStent in Europe," said Joseph Tartaglia, Chief Executive Officer and President of EndoTex Interventional Systems, Inc. "We are proud of our team